Who
Scott Bizily
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, 4D Molecular Therapeutics.
In numbers
- Trades disclosed
- 160
- Buys
- 0
- Sells
- 32
- Bought
- $0
- Sold
- $2.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Jun 2022
- Last trade
- 16 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 20 Oct 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7691,635 at $4.14 | filing |
| 16 Oct 2026filed 20 Oct 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K1,635 at $12.84 | filing |
| 16 Oct 2026filed 20 Oct 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,635 at $0.00 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7691,635 at $4.14 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,635 at $13.65 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,635 at $0.00 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,635 at $0.00 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7691,635 at $4.14 | filing |
| 16 Sep 2026filed 22 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,635 at $13.65 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,790584 at $6.49 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,176584 at $14.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —584 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —584 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,790584 at $6.49 | filing |
| 1 Sep 2026filed 3 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,176584 at $14.00 | filing |
| 17 Aug 2026filed 17 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7691,635 at $4.14 | filing |
| 17 Aug 2026filed 17 Aug 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,635 at $0.00 | filing |
| 17 Aug 2026filed 17 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,635 at $12.20 | filing |
| 17 Aug 2026filed 17 Aug 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,635 at $0.00 | filing |
| 17 Aug 2026filed 17 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7691,635 at $4.14 | filing |
News
4D Molecular Therapeutics (NASDAQ:FDMT) Stock: Insider Scott Bizily Sells 1,635 Sharesthemarketsdaily.com · 20 Oct 2026Critical Contrast: 4D Molecular Therapeutics (NASDAQ:FDMT) & Celldex Therapeutics (NASDAQ:CLDX)FDMT · tickerreport.com · 25 Oct 2026Analyzing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)FDMT · themarketsdaily.com · 24 Oct 2026Contrasting 4D Molecular Therapeutics (NASDAQ:FDMT) and Sangamo Therapeutics (NASDAQ:SGMO)FDMT · tickerreport.com · 14 Oct 2026
1 headline in the last 90 days name Scott Bizily; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.